Skip to main content

Allergy · London

Penicillin allergy de-labelling - private in London.

Around 10% of UK adults carry a penicillin allergy label. Studies suggest 90% of them are not truly allergic - and the false label leads to broader-spectrum antibiotics, more C. diff and MRSA, worse surgical prophylaxis and worse outcomes.

A stethoscope on a clinical desk

Indicative pricing

What private penicillin de-labelling costs in London.

Indicative London ranges.

In short

Low-risk PENFAST 0-1 direct oral challenge: £450-£850. Full skin testing + challenge: £850-£1,600.

Assessment Indicative range
Allergist consultation and PENFAST scoring £250-£450
Direct oral challenge (PENFAST 0-1, low risk) £450-£850
Specific IgE blood test (per determinant) £90-£160
Skin prick + intradermal testing (major + minor) £450-£750
Full pathway: skin testing + oral challenge £850-£1,600
Paediatric penicillin allergy assessment £450-£950

Prices vary by clinic, by allergist and by whether skin testing is needed before challenge. A single-visit PENFAST 0-1 direct oral challenge is now the NICE-preferred pathway for low-risk histories and is the fastest, cheapest route.

Why it matters

The label costs more than you think.

A false penicillin allergy label is not neutral. It steers your care towards second-line antibiotics that are broader, more toxic and less effective - with knock-on effects for infection rates, hospital stays and surgical outcomes.

  • More C. diff and MRSA

    Vancomycin, clindamycin and broad-spectrum cephalosporins raise the risk of Clostridioides difficile colitis and MRSA colonisation compared with penicillins.

  • Worse surgical prophylaxis

    Patients labelled penicillin-allergic have higher surgical site infection rates - particularly in joint replacement, cardiac and cancer surgery.

  • Longer stays, higher cost

    UK and international data show longer hospital admissions and higher antibiotic and re-admission costs in labelled patients - a strong reason for pre-operative de-labelling.

Who is suitable

When de-labelling is safe - and when it is not.

Adults and children with a penicillin label but a low-risk PENFAST history are excellent candidates. Recent anaphylaxis or severe cutaneous reactions are firm exclusions.

  • Childhood rash on amoxicillin

    A blanching non-urticarial rash as a child during an ear or chest infection - the classic false label that is almost never a true allergy.

  • Vague label with no reaction details

    "Penicillin allergy" on the notes with no description of what happened - a low-risk history that responds well to PENFAST-guided challenge.

  • Mild rash or GI upset over five years ago

    A non-severe reaction more than five years back, no airway involvement, no blistering - PENFAST 0 in most cases.

  • Family history mislabelled as personal

    A parent or sibling with a penicillin allergy that has become your label without you ever reacting - easy to lift with a supervised challenge.

  • Adult needing surgical prophylaxis

    You are due joint replacement, cardiac or cancer surgery and the label is forcing vancomycin or clindamycin - worse cover, worse outcomes.

  • Anaphylaxis, SJS, TEN, DRESS or AGEP

    Severe cutaneous adverse reaction or true anaphylaxis - challenge is not offered. The label stays and cross-reactive antibiotics are avoided.

  • Anaphylaxis within the last five years

    Recent anaphylaxis with airway or cardiovascular involvement - de-labelling is not appropriate. Specialist immunology referral instead.

  • Recurrent exposures with progressive reactions

    Each dose worse than the last, or blistering, mucosal involvement or organ dysfunction - stop, do not challenge, refer to immunology.

PENFAST at a glance

Five simple questions. A score of 0 predicts less than 1% risk of true allergy.

  • Age under 65
  • Reaction more than five years ago
  • No severe features (blistering, mucosal)
  • No anaphylaxis features (airway, BP drop)

Pathway options

The right test for the right risk band.

NICE 2023 guidance and BSACI consensus now recommend direct oral challenge as the default for PENFAST 0-1. Higher-risk histories get skin testing or IgE first.

  • PENFAST risk stratification

    A validated score: age under 65, reaction more than five years ago, no severe features, no anaphylaxis. A score of 0 predicts less than 1% risk of true allergy.

  • Direct oral challenge

    For PENFAST 0-1: a single-dose or graded 250-500 mg of amoxicillin, observed in clinic for one to three hours. Now the NICE-preferred standard for low-risk histories.

  • Skin prick testing

    Major and minor determinants of penicillin, benzylpenicillin and amoxicillin applied to the forearm. A wheal at 15 minutes suggests IgE-mediated allergy.

  • Intradermal testing

    A small volume injected into the dermis for anyone with a negative skin prick but a concerning history - more sensitive, slightly more risk of reaction.

  • Specific IgE blood test

    Serum IgE to penicillin G, penicillin V and amoxicillin for those who cannot pause antihistamines or have skin disease preventing testing.

  • Graded amoxicillin challenge

    A 10% dose followed by a 90% dose 30 minutes apart for intermediate-risk patients, with a two-hour observation. Used when skin testing is negative.

  • Paediatric pathway

    A child-friendly workflow: history, PENFAST-P scoring, and a supervised oral amoxicillin challenge for low-risk childhood rash histories.

  • When de-labelling is not offered

    Recent anaphylaxis, SJS, TEN, DRESS, AGEP, blistering or mucosal involvement - the label stays, cross-reactive antibiotics are avoided, alternatives are documented.

Safety and after de-labelling

What happens once the label comes off.

The label is removed from your GP record, updated on hospital systems, and you leave with a patient card. From that point on you can safely receive penicillin.

  • Reaction risk in a well-selected challenge

    For PENFAST 0-1 the risk of a true allergic reaction on challenge is under 1%. Any reaction is usually mild and treated immediately in clinic.

  • Antihistamines paused for five days

    Antihistamines suppress skin testing and mask early challenge signs. You are usually asked to pause cetirizine, loratadine and fexofenadine for five days before your appointment.

  • Beta-blockers and ACE inhibitors reviewed

    These drugs can complicate treatment if a reaction occurs. Your allergist reviews them and coordinates any short-term change with your GP.

  • Observation after the last dose

    One to three hours of clinic observation after the final dose covers the immediate IgE-mediated window. You are discharged with a symptom diary for 48 hours.

  • Delayed reactions are rare but possible

    A small number of patients develop a delayed rash 24-72 hours later. It is almost always mild and self-limiting - you should be told exactly what to look for.

  • Label removed from records

    A formal de-labelling letter goes to your GP, and to any hospital that holds your record. The change is reflected in the Summary Care Record.

  • GP records and Summary Care Record

    Your GP updates the allergy field in EMIS or SystmOne. This is what pharmacies, out-of-hours services and admitting teams see - the label really is gone.

  • Patient card to carry

    A wallet card confirming de-labelling, the date, the allergist and the challenge dose. Useful in A&E, at the dentist, or on holiday abroad.

  • Red flags after discharge

    Widespread rash, facial swelling, wheeze, throat tightness or lightheadedness after the challenge - call the clinic or 999 the same day.

Reading your de-labelling letter

Your letter in four parts. Read the last one first.

Whichever pathway you take, the letter the allergist sends to your GP follows the same shape.

A London allergist reviewing a penicillin de-labelling letter

A quiet reminder

Allergy language can read coldly - ask your care team to put it in plain terms.

If you would like someone to talk you through the letter before your GP appointment, ask the clinician who wrote it.

  1. 01 Header

    PENFAST score and risk band

    Your calculated PENFAST score (0-5), the resulting risk band, and whether direct challenge, skin testing or immunology referral was chosen.

  2. 02 Technique

    What was done and what dose

    Which skin tests were applied, the cumulative amoxicillin dose given, the observation interval and any medications used during the visit.

  3. 03 Findings

    Response and any reaction

    Skin test wheals in millimetres, symptoms during observation, vital signs, and the allergist judgement on whether the challenge is negative.

  4. 04 Impression

    De-labelling status and next steps

    Read this first: whether the penicillin label is formally removed, what the GP letter says, and any antibiotic to avoid going forward.

Recognised by major UK insurers

BupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealix

Cover for penicillin de-labelling varies by insurer and by indication - usually funded when there is a clear clinical need.

Frequently asked

Common questions about penicillin de-labelling.

Quick answers on safety, re-sensitisation, insurance cover, children, and what your GP will do with the letter.

  • Is penicillin de-labelling safe?

    For a PENFAST 0-1 history the risk of a true allergic reaction on a supervised oral challenge is under 1%, and reactions are almost always mild and treated immediately in clinic. Adrenaline, oxygen and IV access are ready in the room throughout. Anyone with recent anaphylaxis, SJS, TEN, DRESS or blistering is not offered a challenge - the label stays.

  • Can I become allergic to penicillin again over time?

    Re-sensitisation after a negative challenge is very rare. Follow-up studies of adults and children de-labelled by direct oral challenge show reaction rates on later exposure well under 5%, and most are mild delayed rashes rather than IgE-mediated allergy. The label does not need to be reinstated unless you have a new confirmed reaction.

  • Will private medical insurance cover de-labelling?

    Cover varies. Bupa, AXA Health, Vitality and Aviva usually fund penicillin allergy assessment when there is a clear clinical need - upcoming surgery, cancer treatment or recurrent infections needing narrow-spectrum antibiotics. Pre-authorisation is straightforward with a GP referral.

  • Do you offer this for children?

    Yes. Around 10% of children carry a penicillin allergy label from a childhood rash on amoxicillin, and over 90% are not truly allergic. Paediatric allergy clinics use a child-adapted PENFAST-P score and a supervised oral amoxicillin challenge. It is a calm, day-case visit and children go home the same afternoon with the label removed.

  • What if I had a severe reaction - am I still a candidate?

    No. Severe cutaneous adverse reactions (SJS, TEN, DRESS, AGEP), anaphylaxis within the last five years, blistering, mucosal involvement or organ dysfunction all exclude you from challenge testing. The label stays, cross-reactive antibiotics are avoided, and you may be referred to immunology for further advice and alternatives.

  • Will my GP accept the de-labelling letter?

    Yes. The de-labelling letter follows the BSACI and NICE 2023 template and includes the PENFAST score, the challenge dose and the observation outcome. GPs update the allergy field in EMIS or SystmOne so the change is reflected in the Summary Care Record. You can ask your practice to chase the update if needed.

Related tests and treatments

Looking for something else?